JDRF Blog

Latest in Research News

  • JDRF Research Strategy: Cures and Improving Lives

    May 31, 2019

    They shared new developments and applauded the speed of scientific advancements. At this year’s Strategic Research Session, the tone was dynamic as...

  • JDRF and Gore Invest in Development of Implantable Insulin Delivery System

    January 22, 2020

    PhysioLogic Devices, a JDRF-funded company that is dedicated to transforming the treatment of type 1 diabetes (T1D), wants to develop the ThinPump™—a...

  • Can Prozac Prevent Severe Low Blood Sugar?

    January 13, 2020

    Low blood sugar, called hypoglycemia, occurs in over 90 percent of people with type 1 diabetes (T1D). It can usually be detected...

  • FDA Grants Breakthrough Device Status: iLet Bionic Pancreas

    December 23, 2019

    Earlier this week, Beta Bionics announced that the Food and Drug Administration (FDA) has granted breakthrough device designation to the company’s iLet...

  • FDA Authorizes a Second Artificial Pancreas System

    December 13, 2019

    The Food and Drug Administration (FDA) today authorized an algorithm that enables the second artificial pancreas system: The Control-IQ™ advanced hybrid closed...

  • Production of Insulin in People with Type 1 Diabetes

    November 25, 2019

    Sernova, a clinical-stage regenerative medicine company, has shown in its JDRF-funded clinical trial that its cell replacement therapy, the Cell Pouch System™,...

  • FDA Approves Xeris Pharmaceuticals’ Glucagon to Treat Severe Hypoglycemia

    September 11, 2019

    “The approval of the GVOKE HypoPenTM is an important step forward for people with diabetes. Severe hypoglycemia is a terrifying and dangerous...